These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8912183)

  • 1. Cellular uptake and localization of liposomal-methylphosphonate oligodeoxynucleotides.
    Tari AM; Andreeff M; Kleine HD; Lopez-Berestein G
    J Mol Med (Berl); 1996 Oct; 74(10):623-8. PubMed ID: 8912183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of cellular uptake of modified oligodeoxynucleotides containing methylphosphonate linkages.
    Shoji Y; Akhtar S; Periasamy A; Herman B; Juliano RL
    Nucleic Acids Res; 1991 Oct; 19(20):5543-50. PubMed ID: 1658734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liposomal delivery of oligodeoxynucleotides.
    Tari A; Khodadadian M; Ellerson D; Deisseroth A; Lopez-Berestein G
    Leuk Lymphoma; 1996 Mar; 21(1-2):93-7. PubMed ID: 8907275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups.
    Tidd DM; Warenius HM
    Br J Cancer; 1989 Sep; 60(3):343-50. PubMed ID: 2551358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The uptake kinetics of chimeric oligodeoxynucleotide analogues in human leukaemia MOLT-4 cells.
    Spiller DG; Tidd DM
    Anticancer Drug Des; 1992 Apr; 7(2):115-29. PubMed ID: 1575885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes).
    Akhtar S; Basu S; Wickstrom E; Juliano RL
    Nucleic Acids Res; 1991 Oct; 19(20):5551-9. PubMed ID: 1945832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Delivery System for Antisense Oligonucleotides: Enhanced Effectiveness of Antisense Oligonucleotides by HVJ-liposome Mediated Transfer.
    Morishita R; Gibbons GH; Horiuchi M; Nakajima M; Ellison KE; Lee W; Kaneda Y; Ogihara T; Dzau VJ
    J Cardiovasc Pharmacol Ther; 1997 Jul; 2(3):213-222. PubMed ID: 10684460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracellular distribution of oligonucleotides delivered by cationic liposomes: light and electron microscopic study.
    Lappalainen K; Miettinen R; Kellokoski J; Jääskeläinen I; Syrjänen S
    J Histochem Cytochem; 1997 Feb; 45(2):265-74. PubMed ID: 9016315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ionic strength on the hybridization of oligodeoxynucleotides with reduced charge due to methylphosphonate linkages to unmodified oligodeoxynucleotides containing the complementary sequence.
    Quartin RS; Wetmur JG
    Biochemistry; 1989 Feb; 28(3):1040-7. PubMed ID: 2713356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular effects of antisense c-myc oligodeoxynucleotides are delivery dependent.
    Koo EW; Edelman ER
    Drug Deliv; 1996; 3(3):149-54. PubMed ID: 26790910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies on anti-human immunodeficiency virus oligonucleotides that have alternating methylphosphonate/phosphodiester linkages.
    Miller PS; Cassidy RA; Hamma T; Kondo NS
    Pharmacol Ther; 2000 Mar; 85(3):159-63. PubMed ID: 10739870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of phosphodiester oligonucleotides: can DOTAP/DOPE liposomes do the trick?
    Remaut K; Lucas B; Braeckmans K; Sanders NN; Demeester J; De Smedt SC
    Biochemistry; 2006 Feb; 45(6):1755-64. PubMed ID: 16460022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracellular availability of unmodified, phosphorothioated and liposomally encapsulated oligodeoxynucleotides for antisense activity.
    Thierry AR; Dritschilo A
    Nucleic Acids Res; 1992 Nov; 20(21):5691-8. PubMed ID: 1454532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides.
    Zhao Q; Matson S; Herrera CJ; Fisher E; Yu H; Krieg AM
    Antisense Res Dev; 1993; 3(1):53-66. PubMed ID: 8495106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of cationic liposomes on intracellular trafficking and efficacy of antisense oligonucleotides in mouse peritoneal macrophages.
    Takagi T; Hashiguchi M; Hiramatsu T; Yamashita F; Takakura Y; Hashida M
    J Drug Target; 2000; 7(5):363-71. PubMed ID: 10721798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells.
    Giles RV; Spiller DG; Grzybowski J; Clark RE; Nicklin P; Tidd DM
    Nucleic Acids Res; 1998 Apr; 26(7):1567-75. PubMed ID: 9512525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uptake of liposomally entrapped fluorescent antisense oligonucleotides in NG108-15 cells: conventional versus pH-sensitive.
    Skalko-Basnet N; Tohda M; Watanabe H
    Biol Pharm Bull; 2002 Dec; 25(12):1583-7. PubMed ID: 12499644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preparation and application of liposome-incorporated oligodeoxynucleotides.
    Tari AM
    Methods Enzymol; 2000; 313():372-88. PubMed ID: 10595367
    [No Abstract]   [Full Text] [Related]  

  • 19. Pegylation of liposomes favours the endosomal degradation of the delivered phosphodiester oligonucleotides.
    Remaut K; Lucas B; Braeckmans K; Demeester J; De Smedt SC
    J Control Release; 2007 Feb; 117(2):256-66. PubMed ID: 17188777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
    Hu Q; Bally MB; Madden TD
    Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.